FDA clears GSK’s Promacta sNDA to treat SAA patients
The US Food and Drug Administration (FDA) has given its clearance to supplemental new drug application (sNDA) for GlaxoSmithKline's (GSK) Promacta (eltrombopag) to treat patients with severe aplastic anaemia (SAA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Anemia | Aplastic Anemia | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals